

Protagen at the European Antibody Congress 2010

Dortmund, November 2, 2010. Protagen AG, a specialist for GMP-compliant protein analysis and *in-vitro* diagnostics is participating at the European Antibody Congress in Geneva. The experts of the company will present the characterization of biotherapeutics – monoclonal antibodies and biosimilars – with protein microarrays and the latest developments of GMP-compliant protein analysis.

The protein microarrays of the UNlchip[®] product family allow faster and more efficient selection of therapeutic antibodies and high affinity biotherapeutic reagents with improved specificity and stability already in the development phase. The special design of the UNlchip[®] products enables the qualitative and quantitative measurement of unspecific binding events of biotherapeutics, so called “off-target activities”. This allows to predict the performance in pharmacokinetic testing and guides the selection of the most promising candidates for further development. The UNlchip[®] technology is also applied to optimize downstream processing and stability testing of antibodies.

The service and method portfolio platforms established at Protagen AG range from GMP-compliant characterization of biotherapeutics to biological potency assays. The combination of high resolution tests for structural analysis with optimized methods for biological activity results in a comprehensive product characterization.

You are cordially invited to meet us at the European Antibody Congress exhibition forum and join the presentation of Dr. Schulz-Knappe, CSO, on November 29th, 12.05 pm, entitled “**Characterization of therapeutic antibody candidates by protein microarrays**“. For further information please refer to <http://www.terrapinn.com/2010/antibodyeu/programme.stm>.

(1,789 Zeichen)

About Protagen AG

Protagen AG (www.protagen.de) is an international leading specialist in the fields of *in-vitro* diagnostics and GMP-compliant protein analysis. The innovations of Protagen are UNlarray[®], a technology platform for the development of novel serum based diagnostics, as well as UNlchip[®], a versatile product family of protein microarrays for faster development of antibodies.

Contact

Dr. Stefan Müllner
CEO
Protagen AG
Otto-Hahn-Str. 15
44227 Dortmund

Tel: +49 (0) 231 9742 6300
Fax: +49 (0) 231 9742 6301
E-Mail: info@protagen.de

Media Enquiries

Bettina Franz
Protagen AG
Otto-Hahn-Str. 15
44227 Dortmund

Tel: +49 (0) 231 9742 6300
Fax: +49 (0) 231 9742 6301
E-Mail: bettina.franz@protagen.de